Join
Live feed
·
PRReleasevia Quantisnow
Akero Therapeutics Inc. logo

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

ByQuantisnow·Wall Street's wire, on your screen.
AKRO· Akero Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AKRO (Akero Therapeutics Inc.) and more on Quantisnow.